Psoriasis Case Study

Introduction

Psoriasis is a chronic, immune-mediated inflammatory disorder that primarily affects the skin but may also involve the joints and other body systems. It can develop at any age, although the first symptoms often appear during adolescence or early adulthood. Pediatric psoriasis deserves careful attention because the visible lesions, itching, pain, treatment demands, and fear of social judgment can affect school attendance, clothing choices, relationships, self-esteem, and emotional well-being.

Psoriasis is not contagious. It develops through an interaction among genetic susceptibility, immune-system dysregulation, environmental triggers, and abnormal activity within the skin. Family history is clinically important because psoriasis has a strong genetic component. However, a family history alone is not sufficient to confirm the diagnosis. A healthcare professional must examine the morphology, location, distribution, duration, and recurrence of the lesions and consider other skin disorders that may look similar.

This case involves E.S., a 15-year-old girl who has attended the clinic four times during the previous year because of recurring inflammatory lesions on her back and chest. The lesions are clearly separated from the surrounding normal skin and are sufficiently irritated that wearing clothing over them is difficult. Her mother also reports that the condition runs in the family.

The clinical presentation strongly suggests psoriasis, particularly chronic plaque psoriasis. However, because the case description does not mention the precise size, thickness, scale, color, or number of lesions, a complete dermatologic examination would still be needed before making a definitive diagnosis.

Case Presentation

E.S. is a 15-year-old girl brought to the clinic for the fourth time within one year because of inflammatory lesions on her back and chest. The lesions are surrounded by normal skin and cause severe irritation. E.S. reports that she can barely tolerate clothing touching the affected areas. Her mother states that similar skin problems occur in the family.

Important information that should also be collected includes:

• When the first lesions appeared.
• Whether the lesions are itchy, painful, burning, or bleeding.
• Whether they have silvery or white scales.
• Whether the lesions are small and drop-shaped or form larger plaques.
• Whether E.S. recently had a sore throat or streptococcal infection.
• Whether the scalp, elbows, knees, nails, skin folds, or genital region are affected.
• Whether scratching or skin injuries trigger new lesions.
• Whether she has joint pain, swelling, morning stiffness, or reduced movement.
• Whether she has recently started or stopped any medication.
• Whether emotional stress worsens the condition.
• How the lesions affect school, sleep, clothing, sports, friendships, and emotional health.

These questions would help confirm the likely type of psoriasis, identify possible triggers, assess severity, and screen for complications.

Considering the Signs and Symptoms Presented, What Is the Likely Diagnosis for E.S.?

The most likely diagnosis is chronic plaque psoriasis, also called psoriasis vulgaris.

Plaque psoriasis commonly produces well-defined, inflamed, thickened, and scaly skin lesions with clear borders separating the affected skin from surrounding normal skin. Although the elbows, knees, scalp, and lower back are common locations, plaques can develop on the chest, abdomen, and back. Pediatric psoriasis may appear in several forms, but chronic plaque psoriasis remains an important presentation in children and adolescents.

Several features in the case support this diagnosis:

1. The lesions are recurrent. E.S. has returned to the clinic four times within one year, suggesting a chronic condition with repeated flares rather than a single short-lived rash.
2. The lesions are clearly separated from normal skin. Plaque psoriasis typically has well-circumscribed borders.
3. The trunk is involved. Plaque psoriasis can affect the back and chest.
4. The lesions are highly irritated. Psoriasis may cause itching, soreness, burning, cracking, and pain, particularly when clothing repeatedly rubs against the affected skin.
5. There is a family history. Psoriasis has a strong genetic component, and a family history increases the likelihood of the disorder.
6. The patient is an adolescent. Pediatric psoriasis frequently begins during adolescence.

The presentation could also represent guttate psoriasis, particularly if E.S. has numerous small, drop-shaped, red, scaly lesions scattered over the trunk. Guttate psoriasis occurs more frequently in children and adolescents and may appear after a streptococcal throat infection. However, guttate psoriasis often begins more suddenly and consists of many small lesions. The case describes recurring inflammatory lesions but does not mention a recent infection or the typical drop-like appearance. Therefore, chronic plaque psoriasis is the stronger conclusion based on the available information.

The differential diagnosis could include pityriasis rosea, tinea corporis, atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, and other scaly inflammatory skin conditions. The diagnosis of psoriasis is normally clinical, meaning that it is based on examination of the skin and medical history. A skin biopsy is occasionally performed when the appearance is uncertain or when another disorder must be excluded.

The healthcare professional should also examine E.S.’s fingernails and toenails for pitting, separation, thickening, or discoloration. Nail changes may provide additional evidence of psoriasis and may be associated with an increased concern for psoriatic joint disease.

What Is the Underlying Pathophysiology of This Inflammatory Process?

The pathophysiology of psoriasis involves excessive keratinocyte proliferation and abnormal differentiation, but the disorder cannot be explained only as uncontrolled skin-cell production. Psoriasis develops through a complex interaction among genetic susceptibility, innate immunity, adaptive immunity, inflammatory cytokines, blood vessels, and keratinocytes.

Keratinocytes are the main cells of the epidermis, which is the outer layer of the skin. Under normal conditions, they are produced in the lower epidermis, mature gradually, and move toward the surface in an organized manner. In psoriasis, inflammatory signals cause these cells to multiply and move through the epidermis too rapidly. They do not mature normally before accumulating at the skin surface. This process contributes to epidermal thickening and the formation of visible scales.

The original explanation correctly recognized hyperproliferation and inflammation as central features. However, increased DNA synthesis is a consequence of immune activation rather than the complete cause of the disease. Healthy skin cells are not simply “decreased.” Instead, keratinocytes proliferate excessively and differentiate abnormally, producing a thickened, inflamed epidermis.

Genetic Susceptibility

Psoriasis has a strong genetic component. Multiple genes influence immune regulation and skin-cell behavior. A person may inherit susceptibility without immediately developing visible psoriasis. Environmental or physiological triggers may then activate the inflammatory process.

The mother’s statement that the disorder runs in the family therefore supports the diagnosis. It does not mean that every family member will develop psoriasis or that the condition follows a simple pattern of inheritance. Several genetic and environmental factors usually interact.

Initiation of the Immune Response

A flare may begin when genetically susceptible skin responds abnormally to an internal or external trigger. Possible triggers include:

• Streptococcal or other infections.
• Emotional or physiological stress.
• Cuts, scratches, burns, or repeated friction.
• Certain medications.
• Withdrawal of systemic corticosteroids.
• Tobacco-smoke exposure.
• Increased body mass index.
• Other environmental or immune stresses.

The appearance of psoriasis at the site of skin trauma is known as the Koebner phenomenon. Because E.S.’s lesions are highly sensitive to clothing, friction could potentially aggravate existing plaques even if it did not initiate the disorder. Pediatric guidelines recognize infection, stress, skin trauma, and environmental factors as important triggers or exacerbating influences.

Dendritic Cells and T-Cell Activation

When psoriasis is initiated, stressed keratinocytes and immune signals activate dendritic cells in the skin. Dendritic cells release inflammatory mediators, including tumor necrosis factor alpha, interleukin-12, and interleukin-23.

Interleukin-23 helps maintain a group of T lymphocytes called T-helper 17 cells. These cells release interleukin-17 and related inflammatory signals. The IL-23/Th17/IL-17 pathway is now considered one of the central mechanisms in psoriasis.

Keratinocyte Activation

Interleukin-17, tumor necrosis factor alpha, interleukin-22, and other cytokines activate keratinocytes. The activated keratinocytes then:

• Proliferate rapidly.
• Differentiate abnormally.
• Release additional cytokines and chemokines.
• Attract more immune cells into the skin.
• Produce antimicrobial peptides.
• Maintain and amplify inflammation.

This creates a self-reinforcing cycle. Immune cells activate keratinocytes, and activated keratinocytes recruit and stimulate additional immune cells. The result is chronic inflammation, epidermal thickening, visible scaling, and recurrent plaques.

Blood-Vessel Changes

Blood vessels in psoriatic lesions become enlarged and more numerous. These vascular changes contribute to the red, pink, purple, brown, or gray appearance of lesions, depending partly on the patient’s natural skin tone.

The increased blood supply also supports the metabolically active and inflamed tissue. Small areas of bleeding may occur when tightly attached scales are removed, although scales should not be forcefully removed during an examination.

Why the Lesions Recur

Psoriasis is a chronic condition characterized by periods of worsening and improvement. Treatment can reduce inflammation and clear visible plaques, but immune memory and genetic susceptibility remain. Triggers may reactivate the inflammatory cycle, causing new lesions or renewed activity in previously affected areas.

This explains why E.S. has presented repeatedly during the year. The recurrence does not necessarily indicate that earlier care was completely ineffective. It may reflect inadequate treatment intensity, poor adherence, unidentified triggers, or the chronic relapsing nature of psoriasis.

What Are the Comorbidities of This Disorder, and Why Do They Occur?

A comorbidity is a separate health condition that occurs more frequently in people with a particular primary disorder than would be expected by chance. Psoriasis was previously considered mainly a skin disease, but it is now recognized as a multisystem inflammatory disorder.

The comorbidities most relevant to a 15-year-old patient include psoriatic arthritis, obesity, metabolic abnormalities, inflammatory bowel disease, and psychological disorders. The American Academy of Dermatology–National Psoriasis Foundation pediatric guideline recommends attention to psoriatic arthritis, metabolic syndrome, cardiovascular risk factors, dyslipidemia, hypertension, insulin resistance, mental health, and inflammatory bowel disease.

Psoriatic Arthritis

Psoriatic arthritis is an inflammatory joint disease associated with psoriasis. It may cause:

• Joint pain.
• Swelling.
• Morning stiffness.
• Reduced movement.
• Swelling of an entire finger or toe.
• Heel pain.
• Back pain.
• Nail changes.

Skin severity does not always predict joint severity. A person with limited skin disease may still develop significant musculoskeletal symptoms. E.S. should therefore be asked about persistent joint pain, swelling, stiffness, or reduced activity.

Early recognition is important because untreated inflammatory arthritis can produce permanent joint damage and functional limitations. A patient with suspected psoriatic arthritis may require evaluation by a pediatric rheumatologist.

Obesity and Metabolic Disorders

Children and adolescents with psoriasis have higher reported rates of obesity and selected metabolic conditions, including insulin resistance, dyslipidemia, hypertension, and metabolic syndrome. These relationships are likely influenced by shared inflammatory pathways, genetic factors, reduced activity, treatment effects, diet, and the psychosocial burden of living with visible skin disease.

The relationship is probably bidirectional. Obesity may increase systemic inflammation and worsen psoriasis, while painful or embarrassing lesions may discourage physical activity. Screening should be respectful and should avoid blaming the adolescent.

For E.S., appropriate monitoring may include growth patterns, BMI, blood pressure, and family risk factors. Laboratory screening should be guided by clinical findings and pediatric recommendations rather than performed automatically without a clear indication.

Psychological Disorders

Psoriasis can affect self-image, confidence, sleep, clothing, sports participation, friendships, and social activities. Adolescents may feel embarrassed about visible lesions or worry that classmates will incorrectly assume the condition is contagious.

Children and adolescents with psoriasis have increased concerns related to depression, anxiety, stigmatization, and reduced quality of life. The burden may be especially serious when lesions are painful, difficult to conceal, or located in sensitive areas.

E.S. reports that she can barely tolerate clothing over the lesions. This symptom may affect school attendance, sleep, concentration, physical activity, and emotional well-being. The clinician should ask privately and respectfully about mood, anxiety, bullying, embarrassment, and self-harm risk.

Inflammatory Bowel Disease

Psoriasis is associated with inflammatory bowel diseases, particularly Crohn’s disease. Shared genetic and immune pathways, including cytokine networks, may contribute to both conditions.

The clinician should ask about chronic abdominal pain, persistent diarrhea, blood in the stool, unexplained weight loss, delayed growth, or severe fatigue when clinically appropriate. These symptoms would require further evaluation rather than being assumed to result from psoriasis.

Uveitis

Uveitis is inflammation involving the middle layers of the eye. It is less common than some other comorbidities but may occur in association with psoriatic disease, particularly when inflammatory arthritis is present.

Symptoms may include eye pain, redness, light sensitivity, blurred vision, or visual changes. These symptoms require prompt medical attention because untreated uveitis may threaten vision.

Celiac Disease and Nonalcoholic Fatty Liver Disease

Studies have reported associations between psoriasis and celiac disease as well as nonalcoholic fatty liver disease. These relationships may involve shared inflammation, immune susceptibility, metabolic factors, or obesity.

However, these conditions should not be diagnosed solely because a patient has psoriasis. Testing should be based on symptoms, risk factors, examination findings, and professional guidelines.

Adult Comorbidities Not Central to This Case

The original discussion mentioned erectile dysfunction. Although sexual dysfunction has been investigated as an adult psoriasis comorbidity, it is not a clinically appropriate focus for this 15-year-old female patient. The case study should prioritize pediatric concerns such as arthritis, metabolic risk, inflammatory bowel disease, and emotional health.

How Is This Disorder Treated, and What Is the Rationale for Using These Treatments?

The treatment of psoriasis aims to reduce inflammation, slow excessive skin-cell proliferation, remove or soften scales, relieve itching and pain, improve quality of life, prolong remission, and reduce the risk of complications.

The correct term is topical therapy, not “tropical therapy.” Topical treatment means medication applied directly to the skin.

The treatment selected for E.S. would depend on:

• The type of psoriasis.
• The percentage of the body affected.
• The thickness and location of the plaques.
• The severity of itching or pain.
• The effect on sleep, school, clothing, and social functioning.
• Previous treatment response.
• Comorbidities.
• The patient’s preferences.
• The ability to follow the treatment plan.

Even a relatively small affected area may be considered clinically significant if the lesions cause severe pain, interfere with daily life, or affect sensitive locations.

Topical Therapy

Topical therapy is generally used first for localized, mild-to-moderate plaque psoriasis.

Emollients and Moisturizers

Emollients soften dry skin, reduce cracking, decrease irritation, and help loosen scale. They do not directly suppress the main immune pathway, but they improve the skin barrier and may make other topical medications easier to tolerate.

Because clothing causes severe irritation for E.S., regular use of a fragrance-free emollient may reduce friction and discomfort. She may also benefit from soft, loose clothing during active flares.

Topical Corticosteroids

Topical corticosteroids reduce inflammation, redness, itching, and plaque thickness. They are commonly used in pediatric psoriasis, often for limited periods and with potency selected according to the patient’s age, lesion location, and severity.

High-potency corticosteroids must be used cautiously in children because prolonged or inappropriate use can cause skin thinning, stretch marks, visible blood vessels, and systemic absorption. Strong preparations should not be applied casually to the face, genital region, or skin folds.

Vitamin D Analogues

Vitamin D analogues, such as calcipotriene, help normalize keratinocyte proliferation and differentiation. They may be used alone or combined with topical corticosteroids.

Combining a vitamin D analogue with a corticosteroid may improve effectiveness and reduce the need for prolonged high-potency steroid use. Pediatric guidelines identify topical corticosteroids combined with vitamin D therapy as a commonly used approach.

Topical Calcineurin Inhibitors

Topical calcineurin inhibitors may be used off label for psoriasis affecting sensitive areas, including the face, genital region, and skin folds. These medications suppress local immune activity without causing the same skin-thinning effects associated with prolonged topical steroid use.

They would not necessarily be the first treatment for plaques on E.S.’s back and chest, but they may be useful if additional sensitive areas are involved.

Tazarotene and Other Topical Treatments

Tazarotene is a topical retinoid that helps normalize abnormal skin-cell growth. It may be combined with a topical corticosteroid to improve effectiveness and reduce irritation. Anthralin and coal-tar preparations may also be used in selected cases, although odor, staining, and skin irritation can make adherence difficult for adolescents.

The treatment plan should consider whether E.S. can realistically apply the medication to her back. Family assistance, spray or foam formulations, or simplified once-daily treatment may improve adherence.

Phototherapy

Phototherapy involves controlled exposure to specific wavelengths of ultraviolet light. It is not the same as uncontrolled sun exposure or indoor tanning.

Narrowband ultraviolet B phototherapy may be considered when psoriasis is widespread, when topical therapy is insufficient, or when repeated topical treatment is impractical. It can reduce immune activation, slow keratinocyte proliferation, and improve plaques.

Phototherapy is effective for moderate-to-severe plaque and guttate psoriasis in pediatric patients. However, it requires repeated visits, eye and skin protection, dose monitoring, and supervision to reduce the risk of burns and excessive ultraviolet exposure.

For E.S., the inconvenience of repeated appointments, school scheduling, transportation, and cumulative exposure should be weighed against the expected benefits.

Systemic Nonbiologic Medication

Systemic medication travels through the bloodstream and affects immune or skin-cell activity throughout the body. It may be considered for moderate-to-severe psoriasis, widespread disease, major quality-of-life impairment, psoriatic arthritis, or failure of topical treatment and phototherapy.

Methotrexate

Methotrexate suppresses immune activity and reduces inflammation. It is commonly used for moderate-to-severe pediatric psoriasis and may also benefit joint disease.

Because it can affect the liver, blood cells, and other organs, patients require pretreatment assessment, laboratory monitoring, and folic-acid supplementation. Pregnancy prevention and reproductive counseling are essential when appropriate because methotrexate can cause severe fetal harm.

Cyclosporine

Cyclosporine is a rapid-acting immunosuppressive medication. It may be useful for severe, unstable, pustular, or erythrodermic psoriasis. However, it can affect blood pressure and kidney function, so it is generally used carefully and with close monitoring.

Acitretin

Acitretin is an oral retinoid that alters keratinocyte growth and differentiation. It may be useful for selected forms of psoriasis, including pustular or extensive disease.

Acitretin is highly teratogenic. Its use in an adolescent girl requires particularly careful specialist evaluation, pregnancy-prevention counseling, and strict monitoring.

Biologic Therapy

Biologic medications target specific components of the inflammatory pathway. Depending on the product, they may block tumor necrosis factor, interleukin-12/23, interleukin-17, interleukin-23, or related immune mechanisms.

These therapies may produce major improvement in moderate-to-severe plaque psoriasis and are particularly useful when conventional treatments fail, are contraindicated, or are poorly tolerated. Several biologic medications have pediatric indications, but approved ages, weight requirements, dosing schedules, and indications differ and continue to evolve. Treatment should therefore be prescribed and monitored by a dermatologist familiar with current pediatric approvals and safety guidance.

Before starting many biologic therapies, patients are evaluated for infections and vaccination status. Monitoring continues during treatment because altering immune activity may increase susceptibility to selected infections.

Treatment Comparison

Are We Seeking a Cure or Symptomatic Relief for Each Treatment Discussed?

Psoriasis currently has no permanent cure. Therefore, the original statement that the treatments are intended to cure the disease is inaccurate.

Treatment aims to control the condition rather than eliminate the underlying genetic and immunologic susceptibility. Patients may experience complete or nearly complete skin clearance during treatment, and remission may continue for a substantial period. However, plaques may return after treatment is stopped or after exposure to a trigger.

The phrase “symptomatic relief” is partly correct but does not fully describe modern treatment. Emollients mainly relieve dryness and irritation, while topical corticosteroids, vitamin D analogues, phototherapy, systemic medications, and biologics act upon inflammatory or proliferative mechanisms involved in the disease.

The goals of treatment include:

• Reducing visible plaques and scale.
• Relieving itching, burning, soreness, and pain.
• Suppressing abnormal immune activation.
• Slowing excessive keratinocyte proliferation.
• Improving sleep and clothing tolerance.
• Restoring participation in school, sports, and social activities.
• Preventing severe flares.
• Identifying and managing joint disease.
• Reducing psychological distress.
• Achieving and maintaining remission.

Therefore, treatment is best described as disease control, inflammatory suppression, symptom relief, and remission management, not a permanent cure.

Nursing and Patient-Education Considerations

Because E.S. is an adolescent, successful treatment will depend partly on whether the plan is understandable, practical, and acceptable to her. The healthcare team should involve her directly rather than speaking only to her mother.

Education should include the following points:

• Psoriasis is not contagious.
• She did not cause the disease.
• Treatment may control the condition even though it does not permanently cure it.
• Medication should be applied exactly as prescribed.
• Strong topical steroids should not be used longer or more widely than directed.
• Plaques should not be aggressively scratched or peeled.
• Fragrance-free moisturizers may reduce dryness and irritation.
• Soft and loose-fitting clothes may reduce friction.
• Possible triggers should be recorded and discussed.
• New joint pain, swelling, or morning stiffness should be reported.
• Severe eye pain, redness, light sensitivity, or visual changes require prompt evaluation.
• Mood changes, withdrawal, bullying, or severe embarrassment should be discussed confidentially.

A written treatment plan may help distinguish which medication should be applied, where it should be used, how often it should be applied, and when it should be stopped. Photographs taken with informed permission may help document clinical progress.

Recommended Plan for E.S.

Based on the information provided, the following steps would be reasonable for the clinical team:

1. Conduct a complete skin, scalp, and nail examination.
2. Document the appearance, number, location, and body-surface area of the lesions.
3. Ask about a recent sore throat or other infection.
4. Assess itching, pain, sleep disruption, and clothing intolerance.
5. Screen for joint pain, swelling, and morning stiffness.
6. Assess the psychological and social effect of the lesions.
7. Confirm the diagnosis clinically and consider dermatology referral.
8. Begin an appropriate topical treatment if the disease is localized.
9. Add regular emollient therapy and skin-care education.
10. Reassess adherence and response after a defined period.
11. Escalate to phototherapy or systemic treatment if the disease is extensive, resistant, or significantly affecting quality of life.
12. Continue long-term monitoring for comorbidities and recurrent flares.

Conclusion

The most likely diagnosis for E.S. is chronic plaque psoriasis, also known as psoriasis vulgaris. Her recurrent inflammatory lesions, clearly defined borders, trunk involvement, severe irritation, adolescent age, and positive family history support this conclusion. However, the diagnosis must be confirmed through direct clinical examination because guttate psoriasis and other inflammatory or scaly skin disorders may produce similar findings.

Psoriasis develops through a complex interaction among genetic susceptibility, immune cells, inflammatory cytokines, blood vessels, and keratinocytes. The IL-23/Th17/IL-17 pathway plays a central role. Inflammatory signals cause excessive keratinocyte proliferation, abnormal differentiation, immune-cell recruitment, and chronic plaque formation.

Psoriasis is also associated with important comorbidities. In an adolescent patient, particular attention should be given to psoriatic arthritis, obesity, metabolic risk, inflammatory bowel disease, anxiety, depression, stigma, and reduced quality of life.

Treatment may include emollients, topical corticosteroids, vitamin D analogues, calcineurin inhibitors, phototherapy, systemic nonbiologic medication, and biologic therapy. The choice depends on disease type, severity, location, quality-of-life effects, previous treatment response, and the patient’s preferences.

Finally, psoriasis cannot currently be cured permanently. Treatment seeks to suppress inflammation, improve or clear the lesions, relieve symptoms, restore quality of life, and maintain remission. E.S. and her family should receive realistic reassurance that, although the condition may recur, it can often be controlled effectively through an individualized and carefully monitored treatment plan.

References

de Oliveira, M. de F. S. P., Rocha, B. de O., & Duarte, G. V. (2015). Psoriasis: Classical and emerging comorbidities. Anais Brasileiros de Dermatologia, 90(1), 9–20. doi:10.1590/abd1806-4841.20153038

Menter, A., Cordoro, K. M., Davis, D. M. R., Kroshinsky, D., Paller, A. S., Armstrong, A. W., Connor, C., Elewski, B. E., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Kaplan, D. H., Kavanaugh, A., Kiselica, M., Kivelevitch, D., Korman, N. J., Lebwohl, M., Leonardi, C. L., Lichten, J., Lim, H. W., Mehta, N. N., Parra, S. L., Pathy, A. L., Farley Prater, E. A., Rupani, R. N., Siegel, M., Stoff, B., Strober, B. E., Wong, E. B., Wu, J. J., Hariharan, V., & Elmets, C. A. (2020). Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal of the American Academy of Dermatology, 82(1), 161–201. doi:10.1016/j.jaad.2019.08.049

Osier, E., Wang, A. S., Tollefson, M. M., Cordoro, K. M., Daniels, S. R., Eichenfield, A., Gelfand, J. M., Gottlieb, A. B., Kimball, A. B., Lebwohl, M., Mehta, N. N., Paller, A. S., Schwimmer, J. B., & Tom, W. L. (2017). Pediatric psoriasis comorbidity screening guidelines. JAMA Dermatology, 153(7), 698–704. doi:10.1001/jamadermatol.2017.0499

Price, B. A., & Jackson, J. B. (2007). Psoriasis. In S. J. Enna and D. B. Bylund (Eds.), XPharm: The comprehensive pharmacology reference (pp. 1–6). Elsevier. doi:10.1016/B978-008055232-3.60794-9

Zhou, X., Chen, Y., Cui, L., Shi, Y., & Guo, C. (2022). Advances in the pathogenesis of psoriasis: From a keratinocyte perspective. Cell Death & Disease, 13, Article 81. doi:10.1038/s41419-022-04523-3

Editorial Staff

Academic Master Education Team is a group of academic editors and subject specialists responsible for producing structured, research-backed essays across multiple disciplines. Each article is developed following Academic Master’s Editorial Policy and supported by credible academic references. The team ensures clarity, citation accuracy, and adherence to ethical academic writing standards

Content reviewed under Academic Master Editorial Policy.

This author does not have any more posts.